Ultimovacs ASA ULTI

OSL: ULTI | ISIN: NO0010851603   30/12/2024
2,330 NOK (-3,92%)
(-3,92%)   30/12/2024

19 december 2024 · Ultimovacs ASA: Notice of extraordinary general meeting on 9 January 2024 - CORRECTION · Persbericht

19 december 2024 · Ultimovacs ASA: Notice of extraordinary general meeting on 9 January 2024 · Persbericht

18 december 2024 · Ulti – Ex. Right To Participate In Potential Repair Offering Today · Persbericht

17 december 2024 · Key information relating to the potential subsequent repair offering to be carried out by Ultimovacs ASA · Persbericht

17 december 2024 · Ultimovacs ASA – Mandatory notification of trade  · Persbericht

17 december 2024 · Ultimovacs Announces Agreement To Combine Its Business With Zelluna Immunotherapy And Intention To Launch Fully Committed Private Placement · Persbericht

6 november 2024 · Ultimovacs ASA Reports Third Quarter 2024 Financial Results and Provides General Business Update · Persbericht

31 oktober 2024 · Ultimovacs ASA: Invitation to third quarter 2024 results webcast presentation · Persbericht

25 oktober 2024 · Ultimovacs Announces Publication of Phase II FOCUS Trial Results on medRxiv · Persbericht

11 september 2024 · Ultimovacs Announces Patient Recruitment Discontinuation in LUNGVAC Trial Investigating UV1 Combined with Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer · Persbericht

9 september 2024 · Ultimovacs Announces Updated Data Analysis on UV1 Phase II NIPU Trial in Mesothelioma at ESMO 2024 · Persbericht

21 augustus 2024 · Ultimovacs ASA Reports Second Quarter 2024 Financial Results and Provides General Business Update · Persbericht

15 augustus 2024 · Ultimovacs ASA: Invitation to second quarter 2024 results webcast presentation · Persbericht

7 augustus 2024 · Ultimovacs Announces Notice of Resignation from Deputy Board Member · Persbericht

5 augustus 2024 · Ultimovacs Announces Topline Data from FOCUS Phase II Trial of UV1 Combined with Pembrolizumab in Patients with Metastatic or Recurrent Head and Neck Cancer · Persbericht

1 augustus 2024 · Ultimovacs Announces Poster Presentation of NIPU Phase II Trial Update at Upcoming ESMO Congress 2024 · Persbericht

24 juni 2024 · Ultimovacs ASA announces revised terms of the employee share option program · Persbericht

11 juni 2024 · Ultimovacs provides update from Phase I study in malignant melanoma: Continued strong overall survival in patients treated with UV1 cancer vaccine and pembrolizumab · Persbericht

1 juni 2024 · Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting · Persbericht

7 mei 2024 · Ultimovacs ASA Reports First Quarter 2024 Financial Results and Provides General Business Update · Persbericht

Mijn selecties